中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 1
Jan.  2017
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2017  >  33(1): 110-115

Clinical effect of ulinastatin in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2017.01.024

  • Department of Gastroenterology, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China

  • Published Date: 2017-01-20
    Abstract

  • Objective To investigate the clinical effect of ulinastatin in preventing pancreatitis after endoscopic retrograde cholangiopancreatography( ERCP). Methods The Cochrane Library,Pub Med,EMBASE,CNKI,VIP,and Wanfang Data were searched for randomized controlled trials( RCTs) on ulinastatin for the prevention of post- ERCP pancreatitis published from 1970 to June 2016. Two researchers selected RCTs,extracted data,and evaluated methodological quality independently,and Rev Man 5. 3 software was used for the meta- analysis. The chi- square test was used for the heterogeneity analysis of RCTs included,and the funnel plots were used to evaluate publication bias. Results A total of six RCTs with 923 patients were included in this analysis. Compared with the placebo,ulinastatin had significantly better effects in preventing post- ERCP pancreatitis( OR = 0. 26,95% CI: 0. 13- 0. 53,P = 0. 000 2),hyperamylasemia( OR = 0. 47,95% CI: 0. 33- 0. 67,P < 0. 001),and abdominal pain( OR = 0. 56,95% CI: 0. 34- 0. 91,P = 0. 020). Compared with gabexate,ulinastatin had similar effects in preventing post- ERCP pancreatitis,hyperamylasemia,and abdominal pain( P = 0. 52,0. 13,and 0. 79);low- dose ulinastatin also had similar effects as gabexate in preventing post- ERCP pancreatitis and hyperamylasemia( P = 0. 49 and0. 25). The funnel plots based on the effect of ulinastatin in preventing post- ERCP pancreatitis were slightly asymmetric,which suggested the presence of publication bias. Conclusion Ulinastatin( ≥15 × 104U) can effectively prevent post- ERCP pancreatitis,hyperlipidemia,and abdominal pain in the general population and it is recommended to start using this drug before surgery.

     

    • FullText(HTML)
    • References(23)
  • [1]MIAO L,WANG F.Recent progress in ERCP for biliary and pancreatic diseases[J].J Clin Hepatol,2014,30(12):1259-1265.(in Chinese)缪林,王飞.经内镜逆行胰胆管造影在胆胰疾病中的应用[J].临床肝胆病杂志,2014,30(12):1259-1265.
    [2]PARSI MA.NSAIDs for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography:ready for prime time?[J].World J Gastroenterol,2012,18(30):3936-3937.
    [3]YOO YW,CHA SW,KIM A,et al.The use of gabexate mesylate and ulinastatin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis[J].Gut Liver,2012,6(2):256-261.
    [4]LIU C,ZHANG L.Somatostatin and its analogues combined with proton pump inhibitor in prevention of post-ERCP pancreatitis:a meta-analysis[J].J Clin Hepatol,2015,31(9):1464-1468.(in Chinese)刘超,张磊.生长抑素及其类似物联合质子泵抑制剂预防经内镜逆行胰胆管造影术后胰腺炎的Meta分析[J].临床肝胆病杂志,2015,31(9):1464-1468.
    [5]ZHANG FB,ZHU B,LIU W,et al.The clinical effect of octreotide combined with indomethacin on pancreatitis and hyperamylasemia after ERCP[J].Clin J Med Offic,2015,43(7):752-753,755.(in Chinese)章福彬,朱斌,刘卫,等.奥曲肽联合吲哚美辛栓剂预防ERCP术后胰腺炎和高淀粉酶血症的临床研究[J].临床军医杂志,2015,43(7):752-753,755.
    [6]CHEN CC,WANG SS,LEE FY.Action of antiproteases on the inflammatory response in acute pancreatitis[J].JOP,2007,8(Suppl4):488-494.
    [7] COTTON PB,LEHMAN G,VENNES J,et al.Endoscopic sphincterotomy complications and their management:an attempt at consensus[J].Gastrointest Endosc,1991,37(3):383-393.
    [8]TSUJINO T,KOMATSU Y,ISAYAMA H,et al.Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography:a randomized,controlled trial[J].Clin Gastroenterol Hepatol,2005,3(4):376-383.
    [9]PARK JY,JEON TJ,HWANG MW,et al.Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications:a prospective,randomized trial[J].Pancreatology,2014,14(4):263-267.
    [10]CHEN X,XIA CM,YAN HF,et al.Clinical effect of ulinastatin versus octreotide in prevention and treatment of pancreatitis after endoscopic retrograde cholangiopancreatography[J].Chin J Rural Med Pharm,2015,22(17):20-21.(in Chinese)陈霞,夏晨梅,颜海帆,等.乌司他丁与奥曲肽预防治疗性内镜逆行胰胆管造影术后胰腺炎效果比较[J].中国乡村医药,2015,22(17):20-21.
    [11]XIONG W,YANG Y,DONG K,et al.Clinical investigation of ulinastatin in preventing and treating hyperamylasemia and acute pancreatitis following endoscopic retrograde cholangio pancreatography[J].Drug Eval,2013,10(2):40-42.(in Chinese)熊伟,杨勇,董科,等.乌司他丁预防ERCP术后高淀粉酶血症及急性胰腺炎的临床研究[J].药品评价,2013,10(2):40-42.
    [12]FUJISHIRO H,ADACHI K,IMAOKA T,et al.Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study[J].J Gastroenterol Hepatol,2006,21(6):1065-1069.
    [13]UEKI T,OTANI K,KAWAMOTO K,et al.Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis:a prospective,randomized trial[J].J Gastroenterol,2007,42(2):161-167.
    [14]DUMONCEAU JM,ANDRIULLI A,DEVIERE J,et al.European Society of Gastrointestinal Endoscopy(ESGE)Guideline:prophylaxis of post-ERCP pancreatitis[J].Endoscopy,2010,42(6):503-515.
    [15]TESTONI PA.Preventing post-ERCP pancreatitis:where are we?[J].JOP,2003,4(1):22-32.
    [16]GRANGER J,REMICK D.Acute pancreatitis:models,markers,and mediators[J].Shock,2005,24(Suppl 1):45-51.
    [17]CAVALLINI G,TITTOBELLO A,FRULLONI L,et al.Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography.Gabexate in digestive endoscopy—Italian Group[J].N Engl J Med,1996,335(13):919-923.
    [18]ANDRIULLI A,CLEMENTE R,SOLMI L,et al.Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis:a multicenter,placebo-controlled,randomized clinical trial[J].Gastrointest Endosc,2002,56(4):488-495.
    [19]MASCI E,CAVALLINI G,MARIANI A,et al.Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis[J].Am J Gastroenterol,2003,98(10):2182-2186.
    [20]OHNISHI H,KOSUZUME H,ASHIDA Y,et al.Therapeutic effects of human urinary trypsin inhibitor on acute experimental pancreatitis[J].Nihon Yakurigaku Zasshi,1983,81(3):235-244.
    [21]TSUJINO T,KAWABE T,OMATA M.Antiproteases in preventing post-ERCP acute pancreatitis[J].JOP,2007,8(Suppl 4):509-517.
    [22]KUBILIUN NM,ADAMS MA,AKSHINTALA VS,et al.Evaluation of pharmacologic prevention of pancreatitis after endoscopic retrograde cholangiopancreatography:a systematic review[J].Clin Gastroenterol Hepatol,2015,13(7):1231-1239.
    [23]YOO JW,RYU JK,LEE SH,et al.Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients:a prospective,randomized,placebocontrolled trial[J].Pancreas,2008,37(4):366-370.
    • Relative Articles

  • Relative Articles

    [1]Yabo SHI, Yang LI, Huabing LIU, Zhicong WANG, Changwen HUANG. Efficacy and safety of omental wrapping technique for pancreaticojejunal anastomosis in preventing complications after pancreaticoduodenectomy： A Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(1): 129-137. doi: 10.12449/JCH240122
    [2]Wang AiMin, Jiao HaiTao, Fang ChaoRan, Li JianHui. A case of splenic rupture after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2020, 36(6): 1356-1357. doi: 10.3969/j.issn.1001-5256.2020.06.035
    [3]Ren Long, Zhang Miao, Zhang Yun. Application of enhanced recovery after surgery in perioperative period of hepatectomy: a Meta-analysis[J]. Journal of Clinical Hepatology, 2018, 34(3): 573-578. doi: 10.3969/j.issn.1001-5256.2018.03.025
    [4]Hu Cui, Bao JunJun, Liu XiaoChang, Ding ShaoZhen, Mei Qiao, Xu JianMing. Effect of diclofenac sodium on the level of non-steroidal anti-inflammatory drug-activated gene-1 in patients with post-ERCP pancreatitis[J]. Journal of Clinical Hepatology, 2018, 34(3): 540-543. doi: 10.3969/j.issn.1001-5256.2018.03.018
    [5]Chinese Digestive Endoscopist Committee, Chinese Endoscopist Association, Chinese Physicians′Association, Pancreatic Disease Committee, Chinese Physicians′Association. Expert consensus on perioperative medication for endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2018, 34(12): 2555-2562. doi: 10.3969/j.issn.1001-5256.2018.12.010
    [6]Zhang WeiFeng, Li JiaSu, Liu Feng, Cheng YiFeng, Shen Peng. Research advances in the prevention and treatment of pancreatitis after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2018, 34(3): 658-662. doi: 10.3969/j.issn.1001-5256.2018.03.049
    [7]Li WeiNan, Yang Gang, Li JingDong, Tang Tao, Li Qiang, Li Yong. Safety of fast track surgery in pancreaticoduodenectomy: a Meta-analysis[J]. Journal of Clinical Hepatology, 2017, 33(1): 121-125. doi: 10.3969/j.issn.1001-5256.2017.01.026
    [8]Zhu YiZhou, Wang Ying, Zhu Chang, Xu XiaoRong. An excerpt of JSGE clinical practice guideline for post-ERCP pancreatitis (2017)[J]. Journal of Clinical Hepatology, 2017, 33(12): 2283-2287. doi: 10.3969/j.issn.1001-5256.2017.12.005
    [9]Wang ChunQiu, Ma YingCai, Zhu ZhiYong, Yuan Ling. Risk factors for recurrence of common bile duct stones after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2017, 33(2): 297-299. doi: 10.3969/j.issn.1001-5256.2017.02.019
    [10]Wang QunRu, Zhang Yong, Mou Dong, Chen BeiJin, Ni Hua, Gao Hui. Association between hematobilia and primary disease after therapeutic endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2017, 33(5): 896-898. doi: 10.3969/j.issn.1001-5256.2017.05.021
    [11]Wang Ai, Zhao LiJin. Research advances in pharmacological prevention of pancreatitis after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2017, 33(1): 184-187. doi: 10.3969/j.issn.1001-5256.2017.01.043
    [12]Lin Yang, Wei Wei, Zhang XiaoHui, Wu KangJian, Han Chao, Xu LiJian. Postoperative complications of laparoscopic versus open common hepatic duct-jejunal Roux-en-Y anastomosis: a Meta-analysis[J]. Journal of Clinical Hepatology, 2016, 32(10): 1959-1963. doi: 10.3969/j.issn.1001-5256.2016.10.029
    [13]Pancreatic Disease Committee of Chinese Medical Doctor Association, Chinese Society of Digestive Endoscopy, Chinese Medical Association. Expert consensus on pharmacological prevention of pancreatitis after endoscopic retrograde cholangiopancreatography (2015, Shanghai)[J]. Journal of Clinical Hepatology, 2016, 32(5): 830-834. doi: 10.3969/j.issn.1001-5256.2016.05.002
    [14]YIERPAN Aishan, Gao Feng. Risk factors for hyperamylasemia after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2016, 32(1): 119-122. doi: 10.3969/j.issn.1001-5256.2016.01.022
    [15]Bi RongXin, Guo QuanZhou, Xue ZhiGuang, Hou ZhiQiang. Analysis of incidence and risk factors for ERCP-related adverse events in patients with primary sclerosing cholangitis[J]. Journal of Clinical Hepatology, 2015, 31(2): 189-192. doi: 10.3969/j.issn.1001-5256.2015.02.011
    [16]Liu Chao, Zhang Lei. Somatostatin and its analogues combined with proton pump inhibitor in prevention of post-ERCP pancreatitis: a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(9): 1464-1468. doi: 10.3969/j.issn.1001-5256.2015.09.024
    [17]Wu JuShan, Li Lei, Song YanMing, Feng Li, Li Bing. Comparative study on safety of endoscopic retrograde cholangiopancreatography in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1267-1271. doi: 10.3969/j.issn.1001-5256.2014.12.009
    [18]Li XiaoQing, Qian JiaMing. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline-Updated June 2014[J]. Journal of Clinical Hepatology, 2014, 30(12): 1236-1239. doi: 10.3969/j.issn.1001-5256.2014.12.002
    [19]Ye Gang, Ma Yu, Tang ChengJia, Du ChengYou. Clinical outcomes of laparoscopic hepatectomy and open hepatectomy for hepatocellular carcinoma: A meta-analysis[J]. Journal of Clinical Hepatology, 2013, 29(3): 184-190.
    [20]Wang Meng, Wang GuangYi, Qiu Wei, Zhang Ping. Efficiency analysis of precut sphincterotomy in ERCP with difficult cannulation[J]. Journal of Clinical Hepatology, 2012, 28(1): 14-16.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(4)

    1. 郑子恢，高峰，赵紫楠，张碧华，金鹏飞. 乌司他丁预防内镜逆行胰胆管造影术后胰腺炎的循证学评价. 中国医院用药评价与分析. 2023(11): 1334-1337 .
    2. 李宇海，钟承彪，李炳金，黄卫，江项武. 乌司他丁联合血栓通治疗老年急性胰腺炎疗效及对炎症指标影响. 内蒙古医学杂志. 2019(04): 425-426 .
    3. 庄瑛瑛，许文集. 早期肠内营养联合加贝酯治疗急性胰腺炎的临床价值. 中外医学研究. 2019(30): 46-48 .
    4. 何清，王立为. 营养支持、生长抑素联合乌司他丁治疗重症急性胰腺炎疗效分析. 临床军医杂志. 2018(03): 248-250+254 .

    Other cited types(1)

  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-040510152025
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 3.7 %FULLTEXT: 3.7 %META: 92.3 %META: 92.3 %PDF: 4.0 %PDF: 4.0 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 7.2 %其他: 7.2 %其他: 0.2 %其他: 0.2 %India: 0.2 %India: 0.2 %Russian Federation: 0.2 %Russian Federation: 0.2 %[]: 0.5 %[]: 0.5 %上海: 2.3 %上海: 2.3 %亳州: 0.5 %亳州: 0.5 %加尔各答: 0.5 %加尔各答: 0.5 %北京: 7.5 %北京: 7.5 %南宁: 0.7 %南宁: 0.7 %台州: 0.5 %台州: 0.5 %吉林: 0.9 %吉林: 0.9 %哥伦布: 0.2 %哥伦布: 0.2 %威海: 0.2 %威海: 0.2 %张家口: 6.1 %张家口: 6.1 %成都: 0.2 %成都: 0.2 %新德里: 0.5 %新德里: 0.5 %杭州: 0.5 %杭州: 0.5 %济南: 0.2 %济南: 0.2 %湖州: 0.2 %湖州: 0.2 %漳州: 0.2 %漳州: 0.2 %福州: 0.2 %福州: 0.2 %芒廷维尤: 30.8 %芒廷维尤: 30.8 %芝加哥: 0.2 %芝加哥: 0.2 %莫斯科: 3.3 %莫斯科: 3.3 %衢州: 0.2 %衢州: 0.2 %西宁: 32.9 %西宁: 32.9 %贵阳: 0.2 %贵阳: 0.2 %辽阳: 0.5 %辽阳: 0.5 %长春: 1.4 %长春: 1.4 %长沙: 0.2 %长沙: 0.2 %长治: 0.2 %长治: 0.2 %其他其他IndiaRussian Federation[]上海亳州加尔各答北京南宁台州吉林哥伦布威海张家口成都新德里杭州济南湖州漳州福州芒廷维尤芝加哥莫斯科衢州西宁贵阳辽阳长春长沙长治

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2288) PDF downloads(406) Cited by(5)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2433]YesterdayPV[3993]TodayIP[162]TodayPV[207]Online[22]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return